The time of day that Etidronate is ingested does not influence its therapeutic effect in osteoporosis

Scandinavian Journal of Rheumatology

Volumn 29, Issue 1, 2000, Pages 62-64

  Cook, G J R ^a,b   Blake, G M ^a   Fogelman, I ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Bone densitometry; Etidronate; Intestinal absorption; Osteoporosis

Indexed keywords

ETIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG EFFECT; FEMALE; FOOD DRUG INTERACTION; HUMAN; INGESTION; INTESTINE ABSORPTION; MAJOR CLINICAL STUDY; MALE; NIGHT; OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0033982067     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/030097400750001824     Document Type: Article

References (10)

1. 1. Fogelman I, Smith L, Mazess R, et al. Absorption of ral diphosphonate in normal subjects. Clin Endocrinol 1986;24:57-62.
2. 2. Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995;58:288-98.
3. 3. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75-85.
4. 4. Gertz BJ, Holland SD, Kline WF, et al. Clinical pharmacology of alendronate sodium. Osteoporos Int 1993;3:S13-6.
5. 5. Recker RR, Saville RD. Intestinal absorption of disodium ethane-1-hydroxyl-1 1-diphosphonate (disodium etidronate) using a deconvolution technique. Toxicol Appl Pharmacol 1973;24:580-9.
6. 6. Osterman T, Juhakoski A, Lauren L, et al. Effect of iron on the absorption and distribution of clodronate after oral administration in rats. Pharmacol Toxicol 1994;74:267-70.
7. 7. Patel R, Blake G, Rymer J, Fogelman I. Long-term precision of DXA scanning assessed over 7 years in 40 postmenopausal women. Osteoporos Int 1994 (in press).
8. 8. van Staa TP. Postmarketing experience with intermittent cyclical etidronate therapy. Rev Contemp Pharmacother. 1998;9:277-86.
9. 9. van Staa TP, Abenhaim L, Cooper C. Upper gastrointestinal adverse events and cyclical etidronate. Am J Med 1997;103:462-7.
10. 10. Dunn CJ, Fitton A, Sorkin EM. Etidronic acid: a review of its pharmacological properties and therapeutic efficacy in resorptive bone diseases. Drugs Aging 1994;5:446-74.